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Abstract: Physiotherapy has long been considered a cornerstone of condition management for 
people with cystic fibrosis (CF). The presentation of CF has changed over time with an increased 
life expectancy and increased expectations of people with CF to have a complete lifestyle. In 
turn, the scope of strategies used in physiotherapy for CF have also changed dramatically over 
the years, moving away from routine postural drainage and manual techniques toward an indi-
vidualized regimen including the choice of many different forms of airway clearance, such as 
both independent and assisted, exercise, treatments to promote continence and good posture, 
inhalation therapy, oxygen, and noninvasive ventilation. This article describes the techniques and 
overall strategies used by physiotherapists in helping people with CF to manage the symptoms 
and progression of their condition.
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Introduction
Cystic fibrosis (CF) is the most common life-limiting genetic disease in the   Caucasian 
population and is also found in other ethnic groups. It is a multisystem disorder, 
although the main cause of morbidity and mortality is respiratory failure. The median 
life expectancy has increased significantly over the last two decades and is currently 
in the mid-thirties.1 A factor in the improvement of life expectancy is an increase in 
the range and intensity of treatments including nutritional support, physiotherapy, 
antibiotics, and other medications.
Physiotherapy has a long-standing role in the management of CF; conventional 
physiotherapy consisting of postural drainage and manual techniques is described 
in papers from 1970s, but this aspect of management has changed dramatically over 
time alongside the presentation of people with CF. Life expectancy has improved as 
have the expectations of people with CF who generally wish to achieve the normal 
milestones, such as attending school, university and work, getting married, and having 
their own family. This provides challenges in balancing the optimal treatment needed 
to maintain the health status required to achieve these milestones with the burden of 
treatment that may also affect lifestyle.
In order to balance treatment demands and lifestyle, methods of management have 
been developed to allow patients who wish to complete treatments at home and/or 
independently to do so where clinically possible thus avoiding extended periods of 
time in the hospital environment and dependence on others that affect the personal life 
of people with CF and may have financial implications for the health care provider. Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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Therefore, contemporary management strategies utilized 
by physiotherapists focus on independence and maintaining 
a normal lifestyle, which is reflected in the use of the tech-
niques described.
There are challenges in conducting high-quality research 
assessing physiotherapeutic techniques in people with CF. CF 
itself has a variable disease process with periods of stabil-
ity, periods of exacerbation, and a varying rate of decline. 
Those with CF are a highly studied population and so it can 
be difficult to recruit them to physiotherapy studies. There 
are also methodological issues with assessing physiotherapy 
interventions; blinding is generally very difficult. The aim 
of this review is to present the range of physiotherapeutic 
interventions, to summarize the evidence that exists, and to 
highlight gaps in the knowledge base.
Airway clearance
Good airway clearance remains a key aim of physiotherapy 
for people with CF and is considered to be integral to their 
overall management.2 There are many techniques available 
that require different patient ability and different types of 
equipment with varying space, portability, noise, appearance 
and cost characteristics. In the United Kingdom (UK), the 
most common forms of airway clearance used are conven-
tional physiotherapy, active cycle of breathing techniques 
(ACBT), autogenic drainage (AD), positive expiratory pres-
sure (PEP) devices, oscillating PEP devices, noninvasive 
ventilation (NIV), and exercise. However physiotherapists 
and people with CF will often choose to try new forms of air-
way clearance that become available. Recently, this has led to 
some use of high-frequency chest wall oscillation (HFCWO), 
intrapulmonary percussive ventilation (IPV), cough assist, 
respiratory muscle training, and other techniques.
The question of whether there is evidence that airway 
clearance should be offered has often been raised. There are 
no long-term trials of physiotherapy for airway clearance 
versus no physiotherapy for airway clearance. This is not 
surprising as physiotherapy is regarded as such an integral 
aspect of CF care that there are questions around the ethics of 
carrying out such a trial and whether those involved, people 
with CF, clinicians, and families, would feel comfortable in 
taking part in such a trial. However, there is evidence from 
two reviews of short-term trials of physiotherapy versus 
no physiotherapy.3,4 These reviews suggest that physio-
therapy does increase sputum transport as compared with 
no physiotherapy.
Recent UK guidance has suggested that an airway clear-
ance technique be taught to improve sputum transport,5 
whereas a second set of recommendations from the 
United States stated that airway clearance should be offered 
to all patients with CF as there is high certainty that the net 
benefit is moderate and at least moderate certainty that the 
net benefit is moderate to substantial.6 So the question is not 
whether we should be offering airway clearance to people 
with CF but rather what type of airway clearance we should 
offer to people with CF.
Conventional physiotherapy
Conventional physiotherapy is a combination of postural 
drainage, components of the ACBT, huffing, directed cough-
ing, and manual techniques7 that can include percussion, 
which is the rhythmical clapping of the chest wall, chest 
shaking, and vibrations, which are vibratory movements 
applied to the chest wall during expiration.8
Conventional chest physiotherapy (CCPT) is comparable 
in terms of effectiveness with other airway clearance 
techniques7 and it remains a combination of techniques that 
some people find useful and have a preference for. However, 
it does have drawbacks that have become more evident as 
people have moved toward independent lifestyles, which are 
not always based around the home. Space and/or equipment 
are required to facilitate postural drainage and it may be dif-
ficult to perform manual techniques independently.
Active cycle of breathing techniques
The ACBT is a cycle of techniques consisting of the following 
three components: (1) breathing control that is tidal volume 
breathing encouraging use of the lower chest with relaxation 
of the upper chest and shoulders, (2) thoracic expansion 
involving deep breathing with an emphasis on inspiration with 
or without breath hold then quiet, relaxed expiration, and 
(3) forced expiration technique consisting of one or two huffs; 
a forced breath out through an open mouth.
ACBT increases the rate of expectoration, so reducing 
time required for physiotherapy,9 and is as effective when 
done independently as with assistance both in terms of energy 
expenditure10 and on the amount of sputum cleared.9 It is 
as effective as AD,11 PEP, cornet or flutter.12 ACBT has the 
advantage of being a relatively simple technique requiring 
no equipment or assistance if used in isolation. It may also 
be combined with other physiotherapy techniques, such as 
postural drainage and percussion.7
Autogenic drainage
AD is a breathing technique that aims to maximize airflow 
within the airways using controlled breathing at differing Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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lung volumes to reach the highest possible airflow in the 
different generations of bronchi.13 The technique involves 
(1) slow inspiration encouraging use of the diaphragm and 
maintaining an open upper airway, (2) an inspiratory pause 
maintaining an open glottis, and (3) an expiratory breath that 
should be at the highest velocity possible without causing 
airway narrowing. This breathing technique is carried out 
at tidal volume within differing lung volumes, so maximiz-
ing expiratory flow. This is often described as a three-phase 
technique as follows: (1) unstick – this phase is carried out 
at low lung volume to help to loosen the peripherally situated 
secretions, (2) collect – breathing around mid-lung volume 
facilitates collection of secretions in the upper airways, and 
(3) evacuate – breathing at high lung volume facilitates clear-
ance of secretions from the upper airways.13
AD is equivalent in effectiveness to conventional phys-
iotherapy in terms of sputum clearance and respiratory 
function.7,14,15 Compared with ACBT, it has been found to be 
a faster method of clearing sputum; however no differences 
in sputum weight cleared or in lung function have been 
identified.11 In a comparison with high pressure PEP 
(Hi-PEP), described later, AD gives an improved lung func-
tion, but sputum clearance is increased with Hi-PEP.16
AD uses no equipment and requires little space as it can 
be performed in sitting and it may also be combined with 
other physiotherapy techniques. However it may be a difficult 
technique for the person with CF to understand and to learn 
particularly if they are not big producers of sputum and so do 
not get audio feedback of the movement of sputum. However 
some physiotherapists do use this technique in very young 
children and, with careful education, most people with CF 
should become competent at using it. A patient preference for 
AD has been shown elsewhere;14,15 in a past study of eighteen 
patients, eight refused to revert back to CCPT from AD to 
complete the trial and another five continued with AD while 
supposedly doing CCPT.14
PeP devices
PEP devices provide a resistance on expiration so theoreti-
cally improving sputum clearance by increasing gas pressure 
behind sputum via collateral ventilation.17,18 PEP may also 
stabilize airways by splinting them open during expiration 
so facilitating sputum clearance.19 PEP was originally defined 
as breathing with a PEP of 10–25 cm H2O,20 but this defini-
tion was expanded for a Cochrane Review in 2006 to include 
pressures from 5–25 cm H2O.16 PEP devices are commonly 
used in the form of a sealed mask held against the face or a 
mouthpiece sealed between the lips. Both types of device 
incorporate a one-way inspiratory valve and an expiratory 
resistance is provided by a resistor or hole of   varying diameter 
that can be altered to tailor the resistance to the patient. 
A manometer can be added to the PEP device to measure the 
expiratory pressure with a given resistor until the appropriate 
pressure is achieved at mid-expiration.   During use, the person 
with CF inhales to a mid-lung volume and actively exhales; 
a number of breaths will be completed followed by relaxed 
breathing and forced expiratory technique as required. This 
cycle is repeated and the number of cycles and exact routine 
of breaths with PEP, relaxed breathing, and forced expiratory 
technique is individualized to person using it. Mouthpiece 
PEP devices may also be used as an attachment to some 
nebulizers, so providing PEP   during nebulization.
Hi-PEP is a modification of a PEP device that includes 
a complete forced expiration against a fixed mechanical 
resistance, which usually generates pressures ranging from 
40–100 cm H2O, and may stimulate coughing.19 The size of 
the resistor is assessed when the patient is performing forced 
volume vital capacity (FVC) maneuvers through each level 
of resistance while the mask is connected to a spirometer or 
pneumatograph. The correct resistor will give a flow volume 
curve with a maximal FVC demonstrating a long spell of 
constant expiratory flow.5
PEP has been demonstrated to be equivalent in effec-
tiveness to other commonly used techniques such as ACBT, 
AD, cornet, and flutter when used over 1 year.21 There have 
been suggestions in papers prior to this study that PEP 
may be superior to oscillating PEP for reducing hospital 
admissions22,23 and superior to other forms of airway clear-
ance for sputum clearance.20,24,25 However, the decision to 
use PEP over another technique needs to be individually 
assessed as the evidence is not robust enough to apply this 
to all patients. There are some concerns that Hi-PEP may be 
of higher risk to the person using it because of the pressures 
involved, but this has not been proven.
PEP is a relatively simple technique using equipment that 
is small enough to be portable. It may be combined with other 
airway clearance techniques and may be used independently. 
PEP has been found to be more acceptable to patients than 
other airway clearance techniques when used in studies of 
over one month in duration.
Oscillating PeP devices
Oral oscillatory PEP devices include flutter, cornet, and 
acapella.16 Theoretically, they work in the same way as PEP 
devices but also shear sputum from the airways by vibration 
and alter the sputum structure by potentially thinning it. Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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The flutter is a pipe-type device made from hard plastic 
with a perforated cover encasing a stainless steel ball within   
a plastic cone. As the person exhales through the flutter, the 
ball bounces and rolls within the cone creating interruptions 
in expiratory flow and producing a PEP of 10–25 cm H2O 
and a vibratory frequency of about 15 Hz. The technique 
used is similar to that of PEP with an inspiration to mid–
volume, but this cannot be made through the PEP as there 
is no inspiratory/expiratory valve. Therefore, the person 
breathes in either through their nose or with an open mouth 
around the mouthpiece. The mouth is then sealed around the 
mouthpiece and an active expiration is made while the person 
tries to keep the cheeks stiff, losing as little vibration through 
the cheeks as possible. A cycle of breaths through the flutter 
is interspersed with relaxed breathing and forced expiratory 
technique; the exact cycle used is individualized.5
The acapella is a plastic device that utilizes a counterweighted 
plate and magnet to create PEP and oscillation with interruptions 
to expiratory flow similar to that seen with flutter. The acapella 
choice has a dial to set expiratory resistance, can be used via 
mouthpiece or mask and may be used with a nebulizer in-line. 
The technique for use is similar to flutter, but unlike the flutter, 
inspiration may be through the device. It also has the advantage 
that it is nonpositional, ie, can be used at any angle.5
The RC-cornet (Bonicur Ltd, Middlesex, United   Kingdom) 
is a flat rubber hose within a plastic arched tube. The hose lies 
flat against the tube until it reaches the curve where it kinks. 
During expiration through the tube, the hose fills with air until 
the kink causes an interruption to the expiratory flow until the 
kink moves along the tube and a new kink is formed closer to 
the mouthpiece. These interruptions cause an oscillation in the 
same way as flutter and acapella. The use of the RC-cornet is 
similar to flutter and acapella, and like the acapella, it is non-
positional and can be used with a nebulizer in-line.5
One study made a long-term (one year) comparison of 
ACBT, AD, RC-cornet, flutter, and PEP and found no sig-
nificant differences in the effectiveness of these techniques 
for airway clearance in adults with CF.21 Other studies have 
demonstrated conflicting results with an increase in sputum 
expectoration shown as compared with other techniques26 
and evidence that oscillating PEP is less effective than PEP 
in terms of hospital admissions and respiratory function.22,23 
These studies assessed flutter although acapella has been 
shown to have similar characteristics and may even have 
slightly better performance characteristics than the flutter 
in terms of the stability of the oscillation wave form.27
All of the identified oscillatory PEP devices are small 
and therefore portable. They are relatively inexpensive and 
adaptable as they can all be used alongside other airway 
clearance techniques. Some people with CF, particularly 
those who have previously used manual techniques, find that 
the sensation of vibration with oscillating PEP as opposed 
to PEP makes them feel that the technique is working. There 
are suggestions of patient preference for oscillating PEP over 
other techniques. However there is noise created by oscillat-
ing PEP devices, particularly RC-cornet, and some patients 
do find this to be unacceptable.
Noninvasive ventilation
NIV refers to ventilatory support given through the upper 
airway provided via a mask, mouthpiece, or similar.28 There 
are many types of ventilator available that provide single 
level, bi-level, or volume support. There is also a wide range 
of interfaces available including types of mouthpiece, nasal 
pillows, oral, nasal, complete, or total facemasks.
Depending on the situation, the physiotherapist will use 
either a mask or more commonly a mouthpiece when using 
NIV for airway clearance. This makes removal of the NIV 
quicker and easier when coughing and clearing sputum. 
The pressures used for airway clearance may be different 
to the pressures used for overnight or similar use and the 
physiotherapist ensures that these pressures are sufficient 
to gain optimal chest expansion during inspiration for the 
person using it. A version of ACBT is generally used with 
NIV facilitating thoracic expansion and decreasing the work 
of breathing during relaxed breathing. Some people may 
also use NIV to achieve a deep inspiration before the forced 
expiratory technique and to recover after cough.
During airway clearance with NIV, fatigue is reduced 
with those using it being less tired after a session of airway 
clearance with NIV as compared without NIV. Maximal 
inspiratory mouth pressures, as an indicator of respiratory 
muscle strength, and oxygen saturations are maintained, and 
respiratory rate is lower during treatment with NIV .29 NIV has 
been shown to improve oxygenation during physiotherapy for 
airway clearance29,30 but has not demonstrated an increased 
sputum clearance despite patients reporting easier sputum 
clearance.29,30 The evidence for the routine use of NIV to aid 
airway clearance is insufficient with no large-scale random-
ized controlled trial (RCTs),28 however, it may be useful for 
certain individuals.
Intermittent positive pressure breathing (IPPB) provides 
intermittent pressure ventilation to augment lung expansion, 
to deliver aerosol medication, or to assist ventilation and is a 
form of NIV . IPPB is used in a similar way to that described 
above for NIV and has widely been replaced by the use of Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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NIV. NIV has proven to be a more adaptable technique, 
which is used for overnight, acute, and chronic ventilation, 
as well as for airway clearance. IPPB does not have this 
adaptability but is still considered for use with atelectasis, 
impaired secretion clearance, or to deliver aerosol medica-
tions where there is respiratory muscle weakness or severe 
hyperinflation.31 There is little evidence for the specific use 
of IPPB in those with CF.5
The devices required to deliver NIV or IPPB are larger 
and more expensive as compared with PEP or oscillating PEP. 
There is a reported patient preference for the use of NIV ,29 but 
a long-term study, where the participant uses the technique 
at home, has not been conducted. The practicalities of using 
a less portable device in the long-term home situation rather 
than in hospital may alter patient preference. NIV and IPPB 
tend to remain techniques that are used acutely for those who 
are struggling with airway clearance due to fatigue, in those 
with significant atelectasis, and in those who also use NIV for 
reasons of respiratory failure or nocturnal hypoventilation.
The use of NIV for airway clearance has been a relatively 
recent development in the use of this equipment. NIV has been 
described for use in those with CF since the 1990s with the 
publication of the article “nasal intermittent positive pressure 
ventilation, a potential bridge to heart–lung transplant”.32 This 
“bridge to transplant” use of NIV continues although there are 
many indications for considering instigation of this treatment 
in CF including acute or chronic respiratory failure, nocturnal 
hypoventilation, during pregnancy, during or postsurgical 
procedure, and as an adjunct to physiotherapy.
NIV is used for the above indications in many CF units, 
but the evidence for its use is still not solid. In 2002, published 
British Thoracic Society guidance stated that, “there are no 
RCTs of NIV versus conventional treatment in these patient 
groups (CF/bronchiectasis)”.28 The guidance also stated that, 
“NIV can be used as an adjunct to physiotherapy, but evidence 
for its effectiveness in clearing secretions is lacking.” The 
guidelines summarize that, “there is insufficient evidence 
to recommend its routine use in these patients.” However, 
these guidelines do not rule out the use of NIV in this patient 
group despite this lack of evidence by recommending that, “a 
trial of NIV may be undertaken in patients with a respiratory 
acidosis (pH , 7.35) secondary to an acute exacerbation of 
bronchiectasis but excessive secretions are likely to limit 
it’s effectiveness and it should not be used routinely.” The 
American Thoracic Society guidelines33 do not discuss NIV 
in relation to CF specifically but do indicate that most patients 
in acute respiratory failure should be given the opportunity of 
a trial of NIV . They also refer to the use of NIV as a ceiling 
of treatment in patients who are not suitable to be intubated 
where there is a suggestion that NIV can reduce dyspnea 
and preserve patient autonomy, given careful and selective 
application. Both the British and American guidelines sug-
gest that NIV may be used during exercise with the rationale 
of decreasing dyspnea, improving oxygenation and thereby 
improving exercise tolerance. There is no current objective 
evidence at present to support this. Since the publication of 
these guidelines a RCT has been carried out.34 This trial of six 
weeks of nocturnal NIV in eight adult patients with stable CF 
with awake hypercapnia demonstrated improvements in chest 
symptoms, dyspnea, nocturnal hypoventilation, and exercise 
capacity following the intervention period with NIV .
NIV can be a difficult treatment for some people with CF 
to accept. It involves more equipment at home, may initially 
be uncomfortable, and may interfere with the person’s lifestyle 
particularly where it is needed for overnight use. It is vital 
that the use and setup of NIV are tailored to the individual 
with thought about the timing of introduction, the timing of 
use, and the type of ventilator and interface. These issues can 
greatly affect acceptance and success of NIV . Ongoing assess-
ment is needed to ensure that the use of NIV is successful and 
that the person using it is able to balance use with the demands 
of other treatments such as overnight feeds.
exercise
Exercise, or physical training, is the participation in a program 
of regular vigorous physical activity designed to improve physi-
cal function, cardiovascular performance, or muscle strength.2 
Exercise programs may consist of cardiovascular exercise, 
strengthening, flexibility, posture, speed, and skill work.
Short-term studies suggest that exercise alone is inferior 
to conventional physiotherapy in terms of airway clearance;6 
however, the addition of exercise to conventional physiother-
apy gives enhanced clearance as compared with conventional 
physiotherapy alone,35–38 and was preferred by patients.36
Exercise can be a popular choice among people with CF 
as an airway clearance technique. It is considered a “normal” 
activity by many and participation can be as part of a group 
activity with friends unlike other physiotherapy interventions. 
Exercise can be a low-cost intervention and is relatively easy 
to adapt to clinical status.
Aside from its use as an airway clearance intervention, 
exercise to increase cardiovascular fitness may alleviate 
dyspnea and depression and may improve exercise tolerance, 
management of diabetes, body image, pulmonary function, 
and delay the onset of osteoporosis.2 Positive effects of aero-
bic and anaerobic training programs may increase exercise Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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  capacity, strength, and lung function. Physical training may 
also aid management of CF-related diabetes, delay onset 
of osteoporosis, and lead to an improved body image and 
decreased anxiety. Past studies are however short-term and are 
not consistent in their findings. Therefore it remains unclear as 
to whether aerobic, anaerobic, or a combination of both is opti-
mal, and there is no evidence to guide prescription of training 
programs in those patients with CF complications.2 Research 
assessing the potential benefits of exercise should be a prior-
ity as it is associated with health management in the general 
population rather than associated with the condition of CF. 
Many people with CF who wish to lead a life that fits in with 
those of their peers therefore identify with this technique.
High-frequency chest wall oscillation
HFCWO is known by a number of other terms including 
high-frequency chest wall compression (HFCWC) and the 
vest. HFCWO is a technique using a pneumatic vest that fits 
over the thorax and that inflates to a positive pressure with 
superimposed air pressure oscillations, which induce rapid 
movement of air in and out of the lungs.39
Past research assessing the effectiveness of HFCWO has 
demonstrated conflicting findings. A number of studies have 
found the effectiveness of HFCWC to be equal to that of CCPT,7 
whereas some studies have favored HFCWO over conventional 
physiotherapy.40–42 A more recent UK study of the use of 
HFCWO during an exacerbation found its efficacy to be less 
than that of the persons’ usual technique in terms of sputum 
clearance.43 A preference for this technique over CCPT has been 
reported;7 however in one study, the participants’ perception was 
that their usual airway clearance technique was more effective.43 
A long-term trial is currently underway in Canada, and this may 
give further information about the efficacy of HFCWO.44
The costs of HFCWO are substantially greater than the 
that of other techniques such as ACBT, AD, PEP and oscil-
lating PEP. It may be difficult to justify this higher cost as the 
technique has not been consistently proven to be superior. It 
is also a larger device that may be noisier and less portable 
than the alternatives. As with the other airway clearance 
techniques, there is a need to individually assess whether 
HFCWO may be a useful technique.
Other less commonly used techniques
Mechanical inexsufflation, also known as cough assist, 
delivers positive pressure followed by negative pressure via a 
mask, mouthpiece, etc to the airways.45 A single small-scale 
observational study assessing the use of cough assist found no 
benefit to the use of cough assist in adults with CF.46 This may 
be a technique to consider where there are difficulties gaining 
optimal airway clearance with the more commonly used tech-
niques. Cough assist is a relatively expensive and less portable 
device and may therefore be difficult for people with CF to use 
as a long-term airway clearance technique.
IPV provides a constant mean airway pressure maintain-
ing partial inspiration whilst internally percussing the airways 
and combining this effect with aerosol inhalation. This is 
achieved by delivering high-flow jets of gas by pneumatic 
flow interrupter combined with a sidestream of room air and 
nebulized medication via a jet venturi.47
Small-scale short-term studies comparing IPV with con-
ventional physiotherapy,47–51 flutter,48 and HFCWC49 agree 
that IPV is as effective as the alternative techniques. Over 
a 6-month period, IPV has been shown to be as effective 
as conventional physiotherapy.47 IPV is a technique using 
a device that is larger, noisier, and more expensive than 
alternative techniques. There is a suggestion that there may be 
a preference toward IPV over conventional physiotherapy,50 
but this preference may be different if assessed in longer term 
studies conducted in the home situation.
Respiratory muscle training has been developed as an 
airway clearance technique following studies assessing the 
use of a fixed-load method to assess inspiratory muscle func-
tion and as its use for inspiratory muscle training. During 
these studies, participants reported increased sputum expec-
toration using repeated inspiratory maneuvers. It has been 
hypothesized that this effect may be similar to that seen with 
exercise.52 Studies looking at the effects of inspiratory muscle 
training show positive effects on sputum expectoration, lung 
function, exercise capacity, inspiratory muscle strength, and 
endurance and anxiety or depression scores.52–54 The clinical 
relevance of improved inspiratory muscle strength or endur-
ance has not been demonstrated, and this technique is not 
used routinely. The equipment involved ranges from relatively 
inexpensive and portable to more expensive devices that are 
less portable.
The use of the three techniques identified would need to 
be individually assessed and monitored very carefully due to 
the lack of data for their use in those with CF. However as the 
presentation of CF can vary dramatically, these less   commonly 
used devices and other newly developed techniques should 
be considered if more standard techniques fail.
Choosing an airway clearance 
technique
The wide range of techniques available assists the physio-
therapist and person with CF to tailor the airway clearance Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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regimen to the person and his/her lifestyle, as well as clinical 
status, but so much choice can also lead to a confusion as 
to which technique to use and why. Recent guidance rec-
ommends that self-administered techniques should be the 
first-line airway clearance techniques offered to improve 
the adherence to treatment and that patient preference for 
techniques should be considered to improve the adherence to 
treatment. Current evidence demonstrates little difference in 
effectiveness between many contemporary airway clearance 
techniques5,6,21 and so factors other than effectiveness will 
affect the choice of techniques.
is the technique suitable for the person’s 
clinical status and for their environment?
Some techniques lend themselves well to particular stages 
of the condition spectrum of CF. There is little evidence for 
which stage each technique may be most appropriate, but 
there are common practices and some practicalities that can 
guide choice of techniques according to clinical status. At the 
mild end of the disease spectrum, issues such as adherence 
and having a lifestyle similar to peers tend to be important. 
Techniques such as exercise, ACBT, AD, and PEP that 
minimize treatment burden are relatively simple and do not 
involve bulky or noisy equipment and are therefore favored. 
For those with more advanced disease, symptoms may 
become more of an issue and, therefore, other techniques, 
for example, the use of NIV to minimize breathlessness, may 
be introduced. Some techniques may be challenging to use 
outside of the hospital environment because of the require-
ment of equipment. For example, IPPB requires oxygen 
cylinders and adapters to be used at home; therefore, NIV 
may be favored.
Does the technique fit  
in with the person’s lifestyle?
Different techniques have characteristics that may fit in 
with specific lifestyles. Some devices, for example, PEP 
or oscillating PEP, are small allowing portability for those 
who may move between houses, for example, when splitting 
time between parent’s and partner’s house, whereas other 
devices such as HFCWO and IPV devices are less portable. 
Some techniques such as ACBT, AD, PEP, oscillating PEP, 
HFCWO, NIV , and IPV allow more independence, although 
some patients like the contact and time with others that 
assisted techniques such as conventional physiotherapy give. 
When living in halls at university or a flat, many patients will 
consider the noise level of the technique a priority. Some 
techniques such as conventional physiotherapy, HFCWO, 
NIV , IPV , and some oscillating PEP devices may be noisier 
than the acceptable level by patients; therefore quieter 
techniques or devices such as AD, ACBT, or PEP may be 
more suitable. Open discussion about the person’s lifestyle 
and encouraging them to discuss ongoing lifestyle changes 
is vital to help them to choose an appropriate technique for 
different periods of their life.
Does the person like the technique?
Consistent adherence to a technique is essential for it to be 
effective. There have been repeated suggestions that personal 
preference for a technique may be of paramount importance.7 
Preference for specific techniques has been suggested in the 
literature; however individuals will respond differently to each 
technique. Preference may be associated with issues raised 
about matching technique to lifestyle but may also be about less 
identifiable issues, such as patient beliefs about the technique, 
other patients’ experiences and appearance of the device.
Does the person think  
that the technique works?
A technique may fit in with the person’s lifestyle, he/she may 
like the technique, and clinically it may have an effect, yet 
despite this, the person using the technique may believe that 
it is not working. This tends to affect adherence but does not 
always require a technique change. This situation may occur 
where the technique has recently been changed, for example 
from conventional physiotherapy to a PEP device, as the 
way the technique feels to the person is different even if it 
is as effective. It is important that there is education about 
the new technique and agreed outcome measures to moni-
tor effectiveness to try to resolve this situation. If the person 
still feels that the technique is not working then a change of 
technique would be needed.
is the technique affordable?
In the UK, airway clearance devices are generally provided free 
of charge as part of the specialist care provision within National 
Health Service (NHS) hospitals. However, there is a cost to the 
NHS that needs to be considered and justified. In countries 
where a health care   service associated with an insurance scheme 
or where airway clearance devices must be bought privately, 
costs will need to be considered so that people with CF can 
access the recommended device. Some techniques such as 
conventional physiotherapy, ACBT, and AD cost only the time 
taken by the physiotherapist to teach and review the technique. 
Other techniques utilize relatively low cost devices, for exam-
ple, PEP and oscillating PEP. Lastly, there are techniques that Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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are more costly and may also involve the ongoing purchase 
of consumables, for example, HFCWO, IPV , and NIV . Cost 
will not be the primary reason for choice of techniques; 
however it is difficult to justify the use of more expensive 
techniques unless additional benefit, efficacy and preference 
are shown over the simpler and less costly techniques.
Posture
Postural disorders in CF are secondary to pulmonary dis-
ease and the complex relationship between posture and 
respiration.55–57 Thoracic kyphosis, vertebral wedging, 
decreased thoracic mobility, and muscle weakness are more 
common in those with CF and are related to worsening lung 
function and clinical symptoms.55,57 These changes are likely 
to be due to an increased work of breathing and the flexed 
posture assumed during excessive coughing.57
The major consequence of postural disorders is back pain, 
and the severity of this pain is associated with pulmonary dete-
rioration, sputum production, and breathlessness. Postural disor-
ders may be responsive to therapy and therefore be reversible.55 
Assessment and an appropriate program of chest mobility and 
strengthening exercises to improve posture and coordination 
significantly improve the posture, chest wall mobility and body 
strength, reduce the need for intravenous antibiotics and slow the 
reduction of forced expiratory volume in one second.58
Despite these benefits, postural assessment and treatment 
are often neglected by people with CF and their clinicians. 
This may be due to the evidence for its benefit being relatively 
recent and so it has not yet become an integrated aspect of 
management within a regimen, which is high burden even 
without the addition of postural treatment.
Continence
The prevalence of urinary incontinence (UI) in women with 
CF is higher than the normal population59–62 and higher than 
in other respiratory patient groups.63 The major cause of UI is 
coughing and symptoms impact mainly on the ability to per-
form airway clearance and lung function testing. Symptoms 
are under reported and subjects are unlikely to seek help with 
the problem. There appears to be no problem with the timing 
of pelvic floor muscle activity or maximum muscle activity 
during huffing and coughing. However, muscle endurance is 
reduced during prolonged coughing, which may be the cause 
of the increased prevalence in those with CF.64
Despite the strong evidence for a high prevalence of UI 
in those with CF, there are few reports of the assessment and 
treatment of the problem. However there is evidence that 
  suggests that the problem is reversible with treatment. One 
study examined the effect of a three-month individualized 
pelvic floor muscle exercise program on the strength and 
endurance of the pelvic muscles65 and found that this pro-
gram reduced symptoms and improved muscle endurance. 
Another study reported improved electromyography activity 
over one and twenty seconds and a decrease in symptoms 
maintained over three months after intervention, following 
a comprehensive program of pelvic floor muscle exercises 
and electrical stimulation.64
Inhalation therapy
Inhalation therapy offers two major advantages: direct transmis-
sion of the drug to the target area and the potential to reduce the 
dose of the drug so minimizing any undesirable side effects.66 
The advantages of delivering medication in this way have led 
to a rapid expansion in the number of medications delivered by 
inhalation so increasing the importance of ensuring that deliv-
ery is optimized. Optimizing inhalation therapy encompasses 
a variety of factors such as type of medication and it’s effects 
on the airways, mucociliary clearance, exercise tolerance, and 
dyspnea, device characteristics, timing of delivery, technique 
during delivery, burden of treatment and adherence.
Medications prescribed by this route include antibiotics, 
mucolytics, bronchodilators, steroids, and antifungals, as well 
as treatments in development such as gene therapy which also 
use the inhaled route. Deposition is an important factor in the 
effectiveness of each of these medications when delivered 
by inhalation. Particle sizes of two–six microns are required 
to target the upper and central airways that give best clinical 
effect. Particles greater than six microns tend to be deposited 
in the mouth and esophageal region with no clinical effect, 
and particle sizes less than two microns show deposition 
in the peripheral airways and alveoli with only some local 
clinical effect but high systemic absorption.67 Therefore, it 
is vital to consider the ability of a device to deliver a high 
proportion of optimally sized particles.
inhalers
Some inhaler devices are more acceptable than others to 
patients. This needs to be balanced against clinical effi-
cacy and the availability of medications through particular 
devices. Drug deposition and delivery are directly influenced 
by inspiratory flow rate. Patients who cannot achieve the 
recommended inspiratory flow for their inhaler may not 
gain maximum benefit from the prescribed drug. Metered-
dose aerosol inhalers (MDIs) are least prone to this effect 
especially when coupled with a spacer device. However this 
bulky combination may be less acceptable to people with CF. Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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Breath-actuated MDIs release the dose of medication above 
the specific flow rate; below this the person will not receive 
the medication. However, this type of device decreases issues 
with technique specifically around coordination between 
inspiration and actuation of the device. Dry-powder inhalers 
are also dependent on sufficient inspiratory flow to remove 
medication from the device; deposition greatly reduces with 
a decreased peak inhalation rate.68,69
Nebulizers
Nebulizers deliver greater doses of medication than inhal-
ers and some medications are, at present, only available for 
delivery by nebulization. There are a number of types of 
nebulizer system, the most simple of which is a compressor 
and nebulizer chamber system considered to be a conven-
tional system. The compressor entrains room air, compresses 
it to a higher pressure and emits the air at a given flow rate. 
Air enters the nebulizer chamber and passes through a small 
hole, a venturi, beyond which the air expands rapidly creating 
a negative pressure that sucks the medication up a feeding 
tube where it is atomized into particles. The particle sizes 
are variable, larger particles impacting on the baffle within 
the nebulizer chamber and the walls of the chamber and 
returned back to the well of the chamber. The smaller par-
ticles are continuously released from the nebulizer chamber 
during both inspiration and expiration by the person using 
the nebulizer system. These systems are relatively cheap but 
tend to be noisy, bulky, require a power source and the particle 
size produced is variable. Because they deliver continuously, 
there is significant wastage of medication and treatment times 
may be prolonged.
Ultrasonic nebulizers use a piezoelectric crystal that vibrates 
creating standing waves within the surface of the medication 
and droplets move away from the crests of these waves becom-
ing an aerosol. Large particles impact on a baffle to be renebu-
lized in the same way as a conventional nebulizer. Ultrasonic 
nebulizers may be smaller and are quieter and quicker than 
conventional systems. However, there is controversy as to 
whether they are suitable to nebulize certain medications.
Newer technologies have been developed to produce 
homogenous particle sizes and to increase speed of nebuliza-
tion. Vibrating mesh technologies aerosolize medication using 
a vibrating, perforated mesh to generate particles. Vibrating 
mesh systems are silent, portable being small, battery powered 
and fast and produce more homogenously sized particles as 
compared with conventional systems. Adaptive aerosol deliv-
ery devices analyze pressure changes relating to airflow and 
deliver timed pulses of aerosol during the first 50%–80% of 
inspiration until the preset dose is delivered. This eliminates 
wastage of medication during exhalation, which occurs with 
continuously delivering nebulizers and optimizes deposition. 
These devices are smaller, quieter, and quicker than conven-
tional systems. They also allow download of adherence data 
including date, time, and duration of each nebulization dose 
taken, as well as whether the dose was complete. This can 
allow a clear picture of how people engage with treatment 
and can assist tailoring of treatment regimens.
Timing of medication
There are few hard and fast rules in the timing and order of 
inhaled medications. Often the effects of the drug and time 
to peak action vary from person to person; therefore advice 
regarding timing is individualized to each person following 
a period of assessment. Possibly the most important point 
regarding inhaled medication is adherence. Therefore, timing 
medications with consideration for a balance between clinical 
effectiveness with the patient’s lifestyle, commitments and 
priorities is the ideal.
There are however some recognized practices with 
regards to timing of inhaled medications. Firstly, dor-
nase alpha is a protein and may be denatured where it 
comes in contact with nebulized antibiotics. Therefore, 
it is advised that a break of at least an hour is observed 
between these two nebulized medications. There is some 
published work looking at timing of dornase alpha around 
airway clearance; one study suggests that it is equally 
effective whether inhaled thirty minutes before or after 
airway clearance,70 whereas another study suggests that 
inhalation thirty minutes before airway clearance improves 
small airway function to a greater extent than inhalation 
thirty minutes after airway clearance.71 It has also been dem-
onstrated that longer time periods of over six hours between 
administration of dornase alpha and airway clearance may 
be more effective than less than six hours.72 However, there 
is agreement between these papers that those using dornase 
alpha should take it regularly and at a time convenient to their 
lifestyle but at least thirty minutes before airway clearance. 
A protocol has been published for a systematic review of the 
evidence regarding timing of dornase alpha, and publication 
of this review may further guide practice.73
It is recognized, but not proven, that nebulized antibiotics 
are best taken after airway clearance to ensure that they are 
not prematurely cleared from the airways. Bronchodilators 
may increase the ease of chest clearance and exercise by 
improving airway patency and, if prescribed, may be useful 
to take before these activities.Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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Oxygen
Progressive lung damage seen in those with CF ultimately 
leads to chronic hypoxemia. This is defined as a partial pres-
sure of oxygen in the blood of less than 8 kPa or 60 mm of 
mercury or where the oxygen saturation of arterial hemoglo-
bin is less than 90%.74 Chronic hypoxemia can lead to pulmo-
nary hypertension and cor pulmonale. Nocturnal hypoxemia, 
which is demonstrated in CF,75–78 may be associated with 
decreased daytime function in patients with CF.79,80
Hypoxemia can be eliminated with supplemental oxygen, 
but the benefits of this have not yet been demonstrated.74 It 
has been shown that oxygen therapy increases function as 
measured by days at work or school,81 but effects have not 
been seen in survival or lung or cardiac function.74 The addi-
tion of supplemental oxygen therapy during exercise improves 
oxygenation and increases exercise tolerance and aerobic 
capacity.74,82 There remains uncertainty about when to insti-
gate oxygen therapy and what the long-term effects are. 
Where it is prescribed, the practical application of oxygen 
therapy can be complex.83,84 People with CF therefore require 
meticulous evaluation and detailed specific prescriptions, 
with relevant assessment for ambulatory oxygen83 ensuring 
access to oxygen devices that will allow a complete 
lifestyle.
Physiotherapy: the future
Numerous physiotherapy techniques have been developed 
and there is a realization that one of the greatest challenges 
is for people with CF to be able to adhere to treatment regi-
mens that may be complicated and/or time-consuming.86 It 
is likely therefore that future developments and research of 
physiotherapy techniques will focus on patient satisfaction, 
quality of life, and adherence. This may involve develop-
ing the techniques available to make any devices involved 
smaller, quieter, easier to use and generally more acceptable 
to people with CF.
Conclusion
As life expectancy for those with CF increases, so additional 
complications are seen which require additional management 
strategies, which in turn increase the burden of treatment. The 
pressures of treatment increasingly come into competition 
with the time and effort required to participate in a complete 
lifestyle and physiotherapy balances precariously between 
these competing pressures. The techniques including airway 
clearance, exercise, inhalation therapy, oxygen therapy, and 
NIV used by physiotherapists are often some of the most 
time-consuming, visual to others and poorly adhered to 
aspects of the management of CF. Yet, these elements of 
management also help to achieve the clinical status required 
for people with CF to lead a complete lifestyle.
Physiotherapists in clinical practice are aware of the 
importance of tailoring management strategies to the indi-
vidual. It should also be accepted that this individual tailoring 
of a physiotherapy routine should be an ongoing process as the 
needs of the person with CF change over time. Research into 
physiotherapy techniques to date has tended to assess efficacy 
of one technique over another with little attention to patient-
reported outcomes. These studies have not demonstrated 
a clear “gold standard” technique to use instead they have 
suggested a similar efficacy between most of the commonly 
used techniques. There are suggestions both from past studies 
and in clinical practice that patient preference, lifestyle, and 
adherence are important in the success of a technique and 
future research should focus on these outcomes. This may 
further assist clinical teams, including physiotherapists and 
people with CF, to tailor treatment plans to the individual.
Disclosure
Tracey Daniels provides advice as a consultant to Philips on 
nebulizer and associated technology development, to Novartis 
and Pharmaxis on inhaled therapies, and to Air Products on 
home oxygen provision.
References
1.  Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and 
survival in the UK: 1947–2003. Eur Respir J. 2007;29:522–526.
2.  Bradley J, Moran F. Physical training for cystic fibrosis. Cochrane 
  Database Syst Rev. 2002;(1):CD002768. doi:10.1002/14651858.
CD002768.pub2.
3.  Thomas J, Cook DJ, Brooks D. Chest physical therapy management of 
patients with cystic fibrosis. A meta-analysis. Am J Respir Crit Care 
Med. 1995;151(3):846–850.
4.  van der Schans CP, Prasad A, Main E. Chest physiotherapy compared 
to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst 
Rev. 2000;(2);CD001401. doi:10.1002/14651858.CD001401.
5.  Bott J, Blumenthal S, Buxton M, et al. Guidelines for the physiotherapy 
management of the adult, medical, spontaneously breathing patient, Joint 
BTS/ACPRC Guideline. Thorax. 2009;64 Supp1:i1–i52.
6.  Flume PA, Robinson KA, O’Sullivan BP, et al. Cystic fibrosis 
pulmonary guidelines: airway clearance therapies. Respir Care. 
2009;54:522–537.
7.  Main E, Prasad A, van der Schans CP. Conventional chest phys-
iotherapy compared to other airway clearance techniques for cys-
tic fibrosis. Cochrane Database Syst Rev. 2005;(1):CD002011. 
doi:10.1002/14651858.CD002011.pub2.
8.  Webber BA, Pryor JA. Physiotherapy for respiratory and cardiac prob-
lems. Edinburgh, New York: Churchill Livingstone; 1993.
9.  Pryor JA, Webber BA, Hodson ME, et al. Evaluation of the forced 
expiration technique as an adjunct to postural drainage in treatment of 
cystic fibrosis. Br Med J. 1979;2:417–418.Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
211
Physiotherapeutic management strategies in cystic fibrosis
  10.  Williams MT, Parsons DW, Frick RA, et al. Acute respiratory infec-
tion in patients with cystic fibrosis with mild pulmonary impairment: 
comparison of two physiotherapy regimens. Aust J Physiother. 
2001;47:227–236.
  11.  Miller S, Hall DO, Clayton CB, et al. Chest physiotherapy in cystic 
fibrosis: a comparative study of autogenic drainage and the active 
cycle of breathing techniques with postural drainage. Thorax. 
1995;50:165–169.
  12.  Pryor JA, Webber BA, Hodson ME, Warner JO. The Flutter VRP1 
as an adjunct to chest physiotherapy in cystic fibrosis. Respir Med. 
1994;88:677–681.
  13.  Pryor JA, Webber BA. Physiotherapy and paramedical issues. In: 
Hodson ME, Geddes D, editors. Cystic Fibrosis. 2nd ed; 2000.
  14.  Davidson AG, Wong LT, Pirie GE, et al. Long-term comparative trial of 
conventional percussion and drainage physiotherapy versus autogenic 
drainage in CF. Pediatr Pulmonol. 1992;14:298.
  15.  McIlwaine PM, Davidson AG, Wong LT, et al. The effect of chest 
physiotherapy by postural drainage and autogenic drainage on oxygen 
saturation in cystic fibrosis. Pediatr Pulmonol. 1991;11:291.
  16.  Elkins MR, Jones A, van der Schans CP. Positive expiratory pres-
sure physiotherapy for airway clearance in people with cystic 
fibrosis. Cochrane Database Syst Rev. 2006;(2):CD003147. 
doi:10.1002/14651858.CD003147.pub3.
  17.  Andersen JB, Qvist H, Kann T. Recruiting collapsed lung through col-
lateral channels with positive end-expiratory pressure. Scan J Respir 
Dis. 1979;60:260–266.
  18.  Groth S, Stafanger G, Dirksen H, Andersen JB, Falk M, Kelstrup M. 
Positive expiratory pressure (PEP-mask) physiotherapy improves ven-
tilation and reduces volume of trapped gas in cystic fibrosis. Bull Eur 
Physiopathol Respir. 1985;21(4):339–343.
  19.  Oberwaldner B, Evans JC, Zach MS. Forced expirations against a vari-
able resistance: a new chest physiotherapy method in cystic fibrosis. 
Pediatr Pulmonol. 1986;2:358–367.
  20.  Falk M, Kelstrup M, Andersen JB, et al. “Improving the ketchup bottle 
method with positive expiratory pressure, PEP, in cystic fibrosis”. Eur 
J Respir Dis. 1984;65(6):423–432.
  21.  Pryor JA, Tannenbaum E, Cramer D, et al. A comparison of five airway 
clearance techniques in the treatment of people with cystic fibrosis. 
J Cyst Fibrosis. 2006;5:S76.
  22.  Costantini D, Brivio A, Brusa D, Delfino R, Fredella C, Russo M. 
PEP-mask versus postural drainage in CF infants a long-term com-
parative trial. Pediatr Pulmonol. 2001;Suppl 22:308.
  23.  McIlwaine PM, Wong LT, Peacock D, Davidson AGF. Long-term 
comparative trial of positive expiratory pressure versus oscillating 
positive expiratory pressure (flutter) physiotherapy in the treatment of 
cystic fibrosis. J Pediatr. 2001;138(6):845–850.
  24.  Hofmeyr JL, Webber BA, Hodson ME. Evaluation of positive expiratory 
pressure as an adjunct to chest physiotherapy in the treatment of cystic 
fibrosis. Thorax. 1986;41:951–954.
  25.  Pfleger A, Theissl B, Oberwaldner B, et al. Self-administered chest 
physiotherapy in cystic fibrosis: a comparative study of high-pressure 
PEP and autogenic drainage. Lung. 1992;170:323–330.
  26.  Konstan MW, Stern RC, Doershuk CF. Efficacy of the flutter device 
for airway mucus clearance in patients with cystic fibrosis. J Pediatr. 
1994;124(5 Pt 1):689–693.
  27.  Volsko TA, DiFiore J, Chatburn RL. Performance comparison of two 
oscillating positive expiratory pressure devices: acapella versus flutter. 
Respir Care. 2003;48(2):124–130.
  28.  British Thoracic Society Standards of Care Committee. Non-invasive 
ventilation in acute respiratory failure. Thorax. 2002;57:192–211.
  29.  Holland AE, Denehy L, Ntoumenopoulos G, et al. Non-invasive ventila-
tion assists chest physiotherapy in adults with acute exacerbations of 
cystic fibrosis. Thorax. 2003;58:880–884.
  30.  Moran F, Bradley J, Piper AJ, et al. Non-invasive ventilation for 
cystic fibrosis. Cochrane Database Syst Rev. 2003;(2):CD002769. 
doi:10.1002/14651858.CD002769.pub2.
  31.  Sorenson HM, Shelledy DC. AARC Clinical practice guideline. 
Intermittent positive pressure breathing. 2003 revision. Respir Care. 
2003;48(5):540–546.
  32.  Hodson ME, Madden BP, Steven MH, Tsang VT, Yacoub MH. Non-
invasive mechanical ventilation for cystic fibrosis patients – a potential 
bridge to transplantation. Eur Respir J. 1991;4(5):524–527.
  33.  American Thoracic Society. International consensus conferences 
in intensive care medicine: Non-invasive positive pressure ven-
tilation in acute respiratory failure. Am J Respir Crit Care Med. 
2000;163:283–291.
  34.  Young AC, Wilson JW, Kotsimbos TC, Naughton MT. Randomised 
placebo controlled trial of non-invasive ventilation for hypercapnia in 
cystic fibrosis. Thorax. 2008;63(1):72–77. Epub 2007 Aug 3.
  35.  Salh W, Bilton D, Dodd M, et al. Effect of exercise and physiotherapy 
in aiding sputum expectoration in adults with cystic fibrosis. Thorax. 
1989;44:1006–1008.
  36.  Bilton D, Dodd ME, Abbot JV , et al. The benefits of exercise combined 
with physiotherapy in the treatment of adults with cystic fibrosis. Respir 
Med. 1992;86:507–511.
  37.  Baldwin DR, Hill AL, Peckham DG, et al. Effect of addition of exercise 
to chest physiotherapy on sputum expectoration and lung function in 
adults with cystic fibrosis. Respir Med. 1994;88:49–53.
  38.  Lannefors L, Wollmer P. Mucus clearance with three chest physiotherapy 
regimes in cystic fibrosis: a comparison between postural drainage, PEP 
and physical exercise. Eur Respir J. 1992;5:748–753.
  39.  Dosman CF. High-frequency chest compression: a summary of the 
literature. Can Respir J. 2005;12(1):37–41.
  40.  Kraig R, Kirkpatrick KR, Howard D, et al. A direct comparison of 
manual chest percussion with acoustic percussion, an experimental treat-
ment for cystic fibrosis. Am J Respir Crit Care Med. 1995;151:P738.
  41.  Kluft J, Beker L, Castagnino M, Gaiser J, Chaney H, Fink RJ. 
A comparison of bronchial drainage treatments in CF. Pediatr 
  Pulmonol. 1995;22:271–274.
  42.  Warwick WJ, Weilinski CL, Hansen LG. Comparison of expectorated 
sputum after manual chest physical therapy and high frequency chest 
compression. Biomed Instrum Technol. 2004;38(6):470–475.
  43.  Osman LP, Roughton M, Hodson ME, et al. High frequency chest wall 
oscillation in cystic fibrosis. J Cyst Fibros. 2008;7:S73.
  44.  Bradley J. High frequency chest wall oscillation in Cystic Fibrosis. 
Thorax. 2010;65:189–190.
  45.  Lapin CD. Assisted cough devices. Pediatr Pulmonol Suppl. 
2004;26:149–151.
  46.  Agent P, Ross E, Chatwin M. The use of mechanical insufflation-
exsufflation on peak cough flow in adults with cystic fibrosis. J Cyst 
Fibros. 2003.
  47.  Homnick DN, White F, de CC. Comparison of effects of an intrapulmo-
nary percussive ventilator to standard aerosol and chest physiotherapy 
in treatment of cystic fibrosis. Pediatr Pulmonol. 1995;20:50–55.
  48.  Newhouse PA, White F, Marks JH, Homnick DN. The intrapulmo-
nary percussive ventilator and flutter device compared to standard 
chest physiotherapy in patients with cystic fibrosis. Clin Pediatr. 
1998;37(7):427–432.
  49.  Varekojis SM, Douce FH, Flucke RL, et al. A comparison of the 
therapeutic effectiveness of and preference for postural drainage and 
percussion, IPV and HFCWC in hospitalised CF patients. Respir Care. 
2003;48(1):24–28.
  50.  Marks JH, Hare KL, Saunders RA, et al. Pulmonary function and 
sputum production in patients with cystic fibrosis: a pilot study 
comparing the PercussiveTech HF device and standard chest phys-
iotherapy. Chest. 2004;125:1507–1511.
  51.  Natale JE, Pfeifle J, Homnick DN. Comparison of intrapulmonary 
percussive ventilation and chest physiotherapy. A pilot study in patients 
with cystic fibrosis. Chest. 1994;105:1789–1793.
  52.  Chatham K, Ionescu AA, Nixon LS, et al. A short-term comparison of 
two methods of sputum expectoration in cystic fibrosis. Eur Respir J. 
2004;23:435–439.Journal of Multidisciplinary Healthcare
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journal
The Journal of Multidisciplinary Healthcare is an international, peer-
reviewed open-access journal that aims to represent and publish research 
in healthcare areas delivered by practitioners of different disciplines. This 
includes studies and reviews conducted by multidisciplinary teams as 
well as research which evaluates the results or conduct of such teams or 
healthcare processes in general. The journal covers a wide range of areas 
and welcomes submission from practitioners at all levels, from all over 
the world. The manuscript management system is completely online and 
includes a very quick and fair peer-review system. Visit http://www.dove-
press.com/testimonials.php to read real quotes from published authors.
Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
212
Daniels
  53.  Enright S, Chatham K, Ionescu AA, et al. Inspiratory muscle training 
improves lung function and exercise capacity in adults with cystic 
fibrosis. Chest. 2004;126:405–411.
  54.  Innes-Asher M, Pardy RL, Coates AL, et al. The effects of inspiratory 
muscle training in patients with cystic fibrosis. Am Rev Respir Dis. 
1982;126:855–859.
  55.  Tattersall R, Walshaw MJ. Posture and cystic fibrosis. J R Soc Med. 
2003;96 Suppl 43:18–22.
  56.  Massery M. Musculoskeletal and neuromuscular interventions: a 
physical approach to cystic fibrosis. J R Soc Med. 2005;98 Suppl 45: 
55–66.
  57.  Rose J, Gamble J, Schultz A, et al. Back pain and spinal deformity in 
cystic fibrosis. Am J Dis Child. 1987;141:1313–1316.
  58.  Demryl A, Ami S, Levi M, et al. Chest strength and mobility training: 
a new approach to airways clearance. J Cyst Fibros. 2006;5:S82.
  59.  White D, Stiller K, Roney F. The prevalence and severity of symptoms 
of incontinence in adult cystic fibrosis patients. Physiother Theory Pract. 
2000;16:35–42.
  60.  Cornacchia 2001 Cornaccia M, Zenorini A, Braagion C, et al. Preva-
lence of urinary incontinence in women with cystic fibrosis. BJU Int. 
2001;88:44–48.
  61.  Orr A, McVean R, Webb AK. A questionnaire survey of the prevalence 
of urinary incontinence in females with cystic fibrosis: a marginalised 
and undertreated problem. Br Med J. 2001;322:1521.
  62.  Moran F, Bradley JM, Boyle L, Elborn JS. Incontinence in adult 
females with cystic fibrosis: a Northern Ireland survey. Int J Clin Pract. 
2003;57:182–183.
  63.  Button BM, Sherburn M, Chase J, McLachan Z, Wilson J. Incontinence 
(urinary and bowel) in women with cystic fibrosis compared to chronic 
obstructive pulmonary disease (COPD) and controls: prevalence, 
severity and bother. Pediatr Pulmonol. 2004;Suppl 27:a359.
  64.  Button BM, Sherburn M, Chase J, Stillman B, Wilson J. Effect of a 
three months physiotherapeutic intervention on incontinence in women 
with chronic cough related to cystic fibrosis and COPD. Pediatr 
  Pulmonol. 2005;113 Suppl 28:a369.
  65.  McVean RJ, Orr A, Webb AK, et al. Treatment of urinary incontinence 
in cystic fibrosis. J Cyst Fibros. 2003;2:171–176.
  66.  Association of Physiotherapists Working with Cystic Fibrosis and the 
CF Nurses Group Working Party. Practical Guidelines for the Use of 
Nebulisers in Cystic Fibrosis. Bexley, Kent: Pharmax Ltd; 1996.
  67.  Chrystyn H. Is inhalation rate important for dry powder inhal-
ers? Using the in-check dial to identify these rates. Respir Med. 
2003;97:181–187.
  68.  Palander A, Mattila T, Karhu M, Muttonen E. 2000, In vitro compari-
son of three salbutamol-containing multidose dry powder inhalers: 
Buventol Easyhaler, Inspiryl Turbuhaler® and Ventoline Diskus. Clin 
Drug Inv. 2000l;20:25–33.
  69.  Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung depo-
sition of budesonide inhaled via Turbuhaler®: a comparison with terb-
utaline sulphate in normal volunteers. Eur Respir J. 1994;7:68–73.
  70.  Fitzgerald D, Hilton J, Jepson B, Smith L. A crossover, randomised, 
controlled trial of dornase alfa before versus after physiotherapy in 
cystic fibrosis. Pediatrics. 2005;116:549–554.
  71.  van der Giessen LJ, de Jongste JC, Gosselink R, et al. RhDNase before 
airway clearance therapy improves airway patency in children with CF. 
Pediatr Pulmonol. 2007;42:624–630.
  72.  Wilson CJ, Robbins LJ, Murphy JM, Chang AB. Is a longer time interval 
between recombinant human deoxyribonuclease (dornase alfa) and 
chest physiotherapy better? A multi-center, randomized crossover trial. 
Pediatr Pulmonol. 2007;42:1110–1116.
  73.  Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic 
fibrosis. Cochrane Database of Syst Rev. 2009;(3):CD007923. 
doi:10.1002/14651858.CD007923.
  74.  Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane 
Database of Syst Rev. 2009;(1):CD003884. doi:10.1002/14651858.
CD003884.pub3.
  75.  Muller NL, Francis PW, Gurwitz D, Levison H, Bryan AC. Mecha-
nisms of hemoglobin desaturation during rapid-eye-movement sleep 
in normal subjects and in patients with cystic fibrosis. Am Rev Respir 
Dis. 1980;121(3):463–469.
  76.  Francis PW, Muller NL, Gurwitz D, Milligan DW, Levison H, 
Bryan AC. Haemoglobin desaturation: its occurrence during sleep in 
patients with cystic fibrosis. Am J Dis Child. 1980;134:734–740.
  77.  Frangolais DD, Wilcox PG. Predictability of oxygen desaturation during 
sleep in patients with cystic fibrosis. Chest. 2001;119(2):434–441.
  78.  Milross MA, Piper AJ, Norman M, et al. Predicting sleep-disordered 
breathing in patients with cystic fibrosis. Chest. 2001;120(4): 
1239–1245.
  79.  Dancey DR, Tullis ED, Heslegrave R, Thornley K, Hanley PJ. Sleep 
quality and daytime function in adults with cystic fibrosis and severe 
lung disease. Eur Respir J. 2002;19:504–510.
  80.  Dobbin CJ, Bartlett D, Melehen K, Grunstein RR, Bye P. The effect 
of infective exacerbations on sleep and neurobehavioural function in 
cystic fibrosis. Am J Respir Crit Care Med. 2005;172:99–104.
  81.  Zinman R, Corey M, Coates AL, et al. Nocturnal home oxygen 
in the treatment of hypoxemic cystic fibrosis patients. J pediatr. 
1989;114(3):368–377.
  82.  Marcus CL, Bader D, Stabile MW, et al. Supplemental oxygen and exer-
cise performance in patients with cystic fibrosis with severe pulmonary 
disease. Chest. 1992;101:52–57.
  83.  British Thoracic Society emergency oxygen guideline group. Guideline 
for emergency oxygen use in adult patients. Thorax. 2008;63 suppl 6: 
vi1–vi68.
  84.  Dodd ME, Haworth CS, Webb AK. “A practical approach to oxygen 
therapy in cystic fibrosis”. J R Soc Med. 1998;91 Suppl 34;30–39.
  85.  Coates AL. “Oxygen therapy, exercise, and cystic fibrosis”. Chest. 
1992;101(1):2–4.
  86.  Quittner AL, Modi AC, Lemanek KL, et al. Evidence-based assessment 
of adherence to medical treatments in pediatric psychology. J Pediatr 
Psychol. 2008;33(9):916–936.